Table 6. Univariate analysis of predictors for 30-day mortality in patients with SAP.
| Characteristics | 30-day mortality (+) (N=5) (%) |
30-day mortality (-) (N=34) (%) |
P |
|---|---|---|---|
| Age (mean, yr) | 58.8±16.9 | 67.9 ± 13.9 | NS |
| Old age (≥ 65 yr) | 2 (40.0) | 23 (67.6) | NS |
| Male | 4 (80.0) | 23 (67.6) | NS |
| Vancomycin MIC ≥ 1.5 µg/mL | 4 (80.0) | 19 (55.9) | NS |
| Teicoplanin MIC ≥ 4 µg/mL | 3 (60.0) | 11 (32.4) | NS |
| MRSA (+) | 3 (60.0) | 24 (70.6) | NS |
| hVISA* (+) | 3 (60.0) | 14 (41.2) | NS |
| Duration of hospital stay before SAP onset | 21.0 ± 24.2 | 7.2 ± 11.5 | 0.0391 |
| Mode of transmission | |||
| Hospital-acquired | 2 (40.0) | 9 (26.5) | NS |
| Comorbidity | |||
| Solid cancer | 2 (40.0) | 5 (14.7) | NS |
| Hematologic malignancy | 0 (-) | 4 (11.8) | NS |
| Diabetes mellitus | 2 (40.0) | 9 (26.5) | NS |
| Cerebrovascular accident | 3 (60.0) | 6 (17.6) | NS |
| Congestive heart failure | 0 (-) | 4 (11.8) | NS |
| Chronic liver disease | 0 (-) | 2 (5.9) | NS |
| Chronic respiratory disease | 0 (-) | 7 (20.6) | NS |
| Chronic kidney disease | 2 (40.0) | 7 (20.6) | NS |
| Previous treatment | |||
| Previous surgery | 2 (40.0) | 7 (20.6) | NS |
| Cancer chemotherapy | 1 (20.0) | 4 (12.8) | NS |
| Immunosuppressive therapy | 0 (-) | 2 (5.9) | NS |
| Prior vancomycin therapy | 2 (40.0) | 10 (29.4) | NS |
| Appropriate empirical therapy | 2 (40.0) | 22 (64.7) | NS |
Categorical variables were compared using Fisher's exact test, and continuous variables were compared using Mann-Whitney U test.
*The hVISA phenotype was identified by macromethod E test.
Abbreviations: SAP, S. aureus pneumonia; MRSA, methicillin-resistant S. aureus; hVISA, heterogeneous vancomycin-intermediate S. aureus; MIC, minimum inhibitory concentration; NS, not significant.